Oncimmune’s EarlyCDT® technology for early lung cancer detection has been extensively documented in peer reviewed publications. The newly published “Cost Effectiveness of an Autoantibody Test (EarlyCDT-Lung) as an Aid to Early Diagnosis of Lung Cancer in Patients with Incidentally Detected Pulmonary Nodules” shows that the test is highly cost-effective for use in pulmonary nodules 8 to 30 mm that are in CT surveillance.
New Study Evaluates the Cost-Effectiveness of EarlyCDT-Lung
Many patients with intermediate-risk pulmonary nodules in the range 8 to 30mm diameter are followed by CT surveillance alone. The risk of cancer in these pulmonary nodules is 9.5%1.
Derek Weycker of Policy Analysis Inc (PIA) shows that the initial use of EarlyCDT-Lung—rather than just CT surveillance alone—can create better outcomes for intermediate-risk patients in a cost-effective manner.
The researchers hypothesized that the use of EarlyCDT-Lung might add life years at a cost-effective rate to intermediate-risk patients that would undergo just CT surveillance otherwise. The use of a decision analytic model allowed them to evaluate the use of the EarlyCDT autoantibody test versus CT surveillance alone.
The results of the model show that the lung cancer blood test delivers additional life years through diagnostic stage shift at a cost of about $24,500 per quality adjusted life year (QALY). This compares very favorably with the cost-effectiveness thresholds of $100,000 to $150,000, which are being advocated for currently, and the $50,000 per QALY that has long been held as a benchmark for the cost-effective use of scarce healthcare resources.
For more information about this study on pulmonary nodules, see the full research article. If you have specific questions about EarlyCDT-Lung or are interested in ordering tests for your patients, contact us today.
1Tanner NT, Aggarwal J, Gould MK, et al. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest 2015;148(6):1405-14